Paul Smith, Ph.D., is the Senior Vice President of Biology at Recludix. Dr. Smith has more than 15 years of drug discovery experience primarily focused on the treatment of inflammatory and autoimmune diseases. Dr. Smith was most recently at Connect Biopharma as the Vice President of Discovery Biology responsible for the prioritization, planning and execution of their preclinical discovery pipeline. Previously, he was the Senior Director of Inflammation and Autoimmunity at Incyte Corporation where he established the discovery research team and was instrumental in the development strategy for certain therapeutics, including FDA-approved Opzelura™ (ruxolitinib cream) for atopic dermatitis and Jakafi™ (oral ruxolitinib) for acute and chronic graft versus host disease. At Novartis, Dr. Smith was the global research lead for Gilenya™ (fingolimod), the first approved sphingosine 1-phosphate (S1P) receptor modulator, and Kesimpta™ (ofatumumab), a differentiated anti-CD20 therapy for the treatment of multiple sclerosis. At Merck Serono, he was the Director of Pharmacology responsible for preclinical inflammation and biomarker discovery. Earlier in his career, Dr. Smith was a Senior Scientist at UCB focused on novel biologics-based treatment strategies for inflammatory diseases. Dr. Smith is an inventor on fifteen issued or pending patents. He received his Ph.D. in Immunology and Neuroscience at Imperial College London, UK and a B.Sc. in Pharmacology from the University of Bath, UK.
« Go Back